These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 37797718)

  • 1. Nonsense mediated decay factor UPF3B is associated with cMyBP-C haploinsufficiency in hypertrophic cardiomyopathy patients.
    Burkart V; Kowalski K; Disch A; Hilfiker-Kleiner D; Lal S; Dos Remedios C; Perrot A; Zeug A; Ponimaskin E; Kosanke M; Dittrich-Breiholz O; Kraft T; Montag J
    J Mol Cell Cardiol; 2023 Dec; 185():26-37. PubMed ID: 37797718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Haploinsufficiency of MYBPC3 exacerbates the development of hypertrophic cardiomyopathy in heterozygous mice.
    Barefield D; Kumar M; Gorham J; Seidman JG; Seidman CE; de Tombe PP; Sadayappan S
    J Mol Cell Cardiol; 2015 Feb; 79():234-43. PubMed ID: 25463273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Premature Termination Codon Mutation in MYBPC3 Causes Hypertrophic Cardiomyopathy via Chronic Activation of Nonsense-Mediated Decay.
    Seeger T; Shrestha R; Lam CK; Chen C; McKeithan WL; Lau E; Wnorowski A; McMullen G; Greenhaw M; Lee J; Oikonomopoulos A; Lee S; Yang H; Mercola M; Wheeler M; Ashley EA; Yang F; Karakikes I; Wu JC
    Circulation; 2019 Feb; 139(6):799-811. PubMed ID: 30586709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variable cardiac myosin binding protein-C expression in the myofilaments due to MYBPC3 mutations in hypertrophic cardiomyopathy.
    Parbhudayal RY; Garra AR; Götte MJW; Michels M; Pei J; Harakalova M; Asselbergs FW; van Rossum AC; van der Velden J; Kuster DWD
    J Mol Cell Cardiol; 2018 Oct; 123():59-63. PubMed ID: 30170119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The A31P missense mutation in cardiac myosin binding protein C alters protein structure but does not cause haploinsufficiency.
    van Dijk SJ; Bezold Kooiker K; Mazzalupo S; Yang Y; Kostyukova AS; Mustacich DJ; Hoye ER; Stern JA; Kittleson MD; Harris SP
    Arch Biochem Biophys; 2016 Jul; 601():133-40. PubMed ID: 26777460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The mechanics of the heart: zooming in on hypertrophic cardiomyopathy and cMyBP-C.
    Suay-Corredera C; Alegre-Cebollada J
    FEBS Lett; 2022 Mar; 596(6):703-746. PubMed ID: 35224729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The HCM-linked W792R mutation in cardiac myosin-binding protein C reduces C6 FnIII domain stability.
    Smelter DF; de Lange WJ; Cai W; Ge Y; Ralphe JC
    Am J Physiol Heart Circ Physiol; 2018 Jun; 314(6):H1179-H1191. PubMed ID: 29451820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MYBPC3-c.772G>A mutation results in haploinsufficiency and altered myosin cycling kinetics in a patient induced stem cell derived cardiomyocyte model of hypertrophic cardiomyopathy.
    Steczina S; Mohran S; Bailey LRJ; McMillen TS; Kooiker KB; Wood NB; Davis J; Previs MJ; Olivotto I; Pioner JM; Geeves MA; Poggesi C; Regnier M
    J Mol Cell Cardiol; 2024 Jun; 191():27-39. PubMed ID: 38648963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Altered C10 domain in cardiac myosin binding protein-C results in hypertrophic cardiomyopathy.
    Kuster DWD; Lynch TL; Barefield DY; Sivaguru M; Kuffel G; Zilliox MJ; Lee KH; Craig R; Namakkal-Soorappan R; Sadayappan S
    Cardiovasc Res; 2019 Dec; 115(14):1986-1997. PubMed ID: 31050699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the effects of a truncating and a missense MYBPC3 mutation on contractile parameters of engineered heart tissue.
    Wijnker PJ; Friedrich FW; Dutsch A; Reischmann S; Eder A; Mannhardt I; Mearini G; Eschenhagen T; van der Velden J; Carrier L
    J Mol Cell Cardiol; 2016 Aug; 97():82-92. PubMed ID: 27108529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How do MYBPC3 mutations cause hypertrophic cardiomyopathy?
    Marston S; Copeland O; Gehmlich K; Schlossarek S; Carrier L
    J Muscle Res Cell Motil; 2012 May; 33(1):75-80. PubMed ID: 22057632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deficient cMyBP-C protein expression during cardiomyocyte differentiation underlies human hypertrophic cardiomyopathy cellular phenotypes in disease specific human ES cell derived cardiomyocytes.
    Monteiro da Rocha A; Guerrero-Serna G; Helms A; Luzod C; Mironov S; Russell M; Jalife J; Day SM; Smith GD; Herron TJ
    J Mol Cell Cardiol; 2016 Oct; 99():197-206. PubMed ID: 27620334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiac myosin-binding protein C mutations and hypertrophic cardiomyopathy: haploinsufficiency, deranged phosphorylation, and cardiomyocyte dysfunction.
    van Dijk SJ; Dooijes D; dos Remedios C; Michels M; Lamers JM; Winegrad S; Schlossarek S; Carrier L; ten Cate FJ; Stienen GJ; van der Velden J
    Circulation; 2009 Mar; 119(11):1473-83. PubMed ID: 19273718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. cMyBP-C ablation in human engineered cardiac tissue causes progressive Ca2+-handling abnormalities.
    De Lange WJ; Farrell ET; Hernandez JJ; Stempien A; Kreitzer CR; Jacobs DR; Petty DL; Moss RL; Crone WC; Ralphe JC
    J Gen Physiol; 2023 Apr; 155(4):. PubMed ID: 36893011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protein Quality Control Activation and Microtubule Remodeling in Hypertrophic Cardiomyopathy.
    Dorsch LM; Schuldt M; dos Remedios CG; Schinkel AFL; de Jong PL; Michels M; Kuster DWD; Brundel BJJM; van der Velden J
    Cells; 2019 Jul; 8(7):. PubMed ID: 31323898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A hypertrophic cardiomyopathy-associated MYBPC3 mutation common in populations of South Asian descent causes contractile dysfunction.
    Kuster DW; Govindan S; Springer TI; Martin JL; Finley NL; Sadayappan S
    J Biol Chem; 2015 Feb; 290(9):5855-67. PubMed ID: 25583989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protein haploinsufficiency drivers identify MYBPC3 variants that cause hypertrophic cardiomyopathy.
    Suay-Corredera C; Pricolo MR; Herrero-Galán E; Velázquez-Carreras D; Sánchez-Ortiz D; García-Giustiniani D; Delgado J; Galano-Frutos JJ; García-Cebollada H; Vilches S; Domínguez F; Molina MS; Barriales-Villa R; Frisso G; Sancho J; Serrano L; García-Pavía P; Monserrat L; Alegre-Cebollada J
    J Biol Chem; 2021 Jul; 297(1):100854. PubMed ID: 34097875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contractile dysfunction in a mouse model expressing a heterozygous MYBPC3 mutation associated with hypertrophic cardiomyopathy.
    Barefield D; Kumar M; de Tombe PP; Sadayappan S
    Am J Physiol Heart Circ Physiol; 2014 Mar; 306(6):H807-15. PubMed ID: 24464755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of MYBPC3 loss-of-function mutations preceding hypertrophic cardiomyopathy.
    Helms AS; Tang VT; O'Leary TS; Friedline S; Wauchope M; Arora A; Wasserman AH; Smith ED; Lee LM; Wen XW; Shavit JA; Liu AP; Previs MJ; Day SM
    JCI Insight; 2020 Jan; 5(2):. PubMed ID: 31877118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiac myosin-binding protein C in hypertrophic cardiomyopathy: mechanisms and therapeutic opportunities.
    Schlossarek S; Mearini G; Carrier L
    J Mol Cell Cardiol; 2011 Apr; 50(4):613-20. PubMed ID: 21291890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.